eligibility_summary
Eligibility: 2–25 y (first 2: 12–25), DMG H3.3K27M post‑RT, HLA‑A0201+, CNS reservoir, off or stable low‑dose dex, off prior therapy (chemo ≥7 d, antibodies ≥3 half‑lives/≤30 d) and recovered, adequate organ function, PS ≥60. Exclude: uncontrolled mass effect, immunodeficiency (HIV/HBV/HCV) or autoimmune on IS, active infection, pregnancy/breastfeeding, symptomatic hydrocephalus, prior transplant, other trials/anticancer drugs (bevac prior ok, off at enrollment).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: KIND T cells—autologous, gene-engineered TCR-T cell therapy, expresses an HLA-A0201–restricted TCR specific for the H3.3K27M neoantigen, endogenous TCR is inhibited to prevent mispairing/off-target reactivity. Given IV after lymphodepletion with cyclophosphamide (alkylating chemotherapy/DNA crosslinker) and fludarabine (purine analog antimetabolite) to deplete host lymphocytes and aid engraftment. Targets: H3.3K27M-mutant peptide presented on MHC class I (HLA-A0201) on diffuse midline glioma cells, engages CD8+ cytotoxic T-cell pathways for tumor cell killing. Lymphodepletion targets host T/B cells to promote expansion/persistence of infused T cells.